Safety is not established by the absence of major problems in small short studies. Selected reports for sermorelin include 110 children treated for a year [3] and 11 older men treated for six weeks [4]. Both reported few problems. Neither was built to find rare or slow-building harms, and no current FDA label exists to summarize them [6].
Short answer: tolerated in small, short studies; long-term safety unknown
Sermorelin was an FDA-approved drug, Geref, until 2009, and FDA later said it was not withdrawn for safety reasons [7]. That history is reassuring as far as it goes. It does not tell you how the drug behaves in healthy adults using it for years, because the selected studies do not establish safety for that setting.
Two other gaps matter as much as the data. Sermorelin sold today is compounded, so its quality depends on the pharmacy that made it. Adult uses for aging or body composition are not FDA-approved; a compounded product does not inherit the withdrawn Geref approval.
What the studies reported
The 1996 pediatric study reported no adverse changes in routine blood chemistry or hormones, no change in fasting glucose, and no excess rise in IGF-1 (Thorner 1996, n=110) [3]. The 1997 study in older men reported no significant adverse effects over six weeks (Vittone 1997, n=11) [4].
A third study used a closely related analog rather than sermorelin itself. Nineteen adults aged 55 to 71 injected placebo for four weeks and then the analog for 16 weeks; the immune-system paper reported no adverse effects [5]. Its companion metabolic report, however, described transient hyperlipidemia that resolved by the end of treatment [2]. These are reports from a small study of a different molecule, not proof that compounded sermorelin is safe long term.
| Study | Who | People | Length | Safety finding |
|---|---|---|---|---|
| Thorner 1996 [3] | Children with growth hormone deficiency (open-label, no control group) | 110 | Up to 1 year | No adverse changes in blood chemistry or hormones; no excess IGF-1; well tolerated |
| Vittone 1997 [4] | Healthy men aged 64 to 76 (no control group) | 11 | 6 weeks | No significant adverse effects |
| Khorram 1997 [5] | Healthy adults aged 55 to 71; related analog, not sermorelin | 19 | 16 weeks after 4 weeks of placebo | Companion metabolic report described transient hyperlipidemia [2] |
| Chen 1993 [12] | GH-deficient children randomized to GHRH(1-29) or growth hormone | 60 total; 40 on GHRH | 6 months | GHRH antibodies in 39/40 recipients, three mild injection-site reactions; no serious side effects reported |
| Koutkia 2004 [13] | Men with HIV lipodystrophy; randomized Geref versus placebo | 31 randomized | 12 weeks | No significant between-group glucose, insulin or lipid change; a small metabolic result does not exclude uncommon or long-term harms |
These reports do not establish long-term safety or the quality of currently dispensed compounded sermorelin.
How far sermorelin moves your hormones
Acting through the pituitary does not by itself establish safety. In Vittone’s eleven older men, six weeks raised nighttime GH but not IGF-I [4]. Other regimens did raise IGF-I [1], and the pediatric study reported no excessive IGF-I elevation [3]. These are protocol-specific findings, not a guarantee that hormonal feedback prevents harm.
The related analog study saw a larger effect: IGF-1 rose 28% within four weeks in adults aged 55 to 71 [5]. A rise is the intended effect. These selected studies do not establish the consequences of sustained long-term elevation, so ask whether your prescriber will measure IGF-1 before and during treatment.
What historical approval can’t tell you
An approved drug carries a label with warnings, precautions and an adverse-reaction table. Sermorelin's labels left the market with Geref, whose approvals were withdrawn effective June 18, 2009 [8]. DailyMed, the federal library of current drug labels, has no sermorelin label today [6].
A clinic’s symptom summary is not a measured risk estimate for the preparation it sells. Ask which historical or current evidence supports the warnings, and what the prescriber will monitor. For the full status history, see whether sermorelin is FDA-approved.
Compounded sermorelin: the quality question
Compounded sermorelin is not FDA-reviewed for quality before sale [9]. Ask for the pharmacy's name and whether it is a 503A pharmacy or a 503B outsourcing facility. On FDA's 503B list, sermorelin acetate sits in Category 1, under evaluation [11]; on the 503A list it is in no category [10].
Providers differ in how much of this they publish. Our checks of CoreAge Rx, Eden and AgelessRx show what each one's pages say about the pharmacy behind its sermorelin. The checks themselves are explained on how we check.
What happens when you stop?
These studies do not establish a reliable adult withdrawal or rebound pattern; the 1997 study in older men reported six weeks on treatment [4]. Claims predicting rebound, withdrawal symptoms or lasting benefit require evidence beyond this report.
Hair loss, sleepiness and other reported effects
The selected reports do not provide a reliable incidence of hair loss or drowsiness. Online symptom lists are not a measured frequency for a particular preparation. Report new symptoms to the prescriber; their timing alone does not prove or exclude a drug effect.
Questions to raise with a prescriber before starting
A current compounded product has no FDA-approved product-specific label. Historical approval does not replace a clinician’s assessment of contraindications, other medicines, pregnancy and monitoring. Bring your full history and ask how it changes the plan.
- Do I have a personal or family history of cancer, and does that change whether a growth-hormone-raising drug makes sense for me?
- I'm pregnant, breastfeeding or planning a pregnancy. Has sermorelin been studied in that situation?
- I have diabetes or prediabetes. Which labs will you track, and how often?
- Which pharmacy makes the product, and is it a 503A pharmacy or a 503B outsourcing facility?
- What is the goal, and how long before we judge whether it is working?
Is sermorelin safe with GLP-1s like tirzepatide?
The reviewed sources do not establish the safety or effectiveness of adding sermorelin to tirzepatide, semaglutide or another GLP-1 drug. A missing identified trial establishes neither benefit nor harmlessness. Tell the prescriber about every medication and ask what evidence supports the combination and how it would be monitored.
| Claim | Where you see it | Human evidence | How much to trust it |
|---|---|---|---|
| "Safe long term" | Seller blogs | Selected studies followed children up to one year and older adults for shorter periods; they do not establish rare or long-term harms [3] [5] | Unknown |
| "No side effects" | Clinic pages | Small studies reported few; no label exists to list them [4] [6] | Not much |
| "Safer than HGH" | Clinic pages | A pediatric head-to-head trial exists, but it cannot establish general adult comparative safety [12] | Unproven |
| "Pharmacy-grade" | Sellers | Compounded, not FDA-reviewed for quality [9] | Depends on the pharmacy |
Whether sermorelin does what sellers promise is a separate question from whether it is safe. The evidence on benefit is covered in does sermorelin work.
Other short adult protocols answer narrower questions
Corpas and colleagues studied ten older men through two 14-day courses of GHRH(1-29), in randomized dose order, with nine younger men providing a baseline comparison. The higher regimen increased growth-hormone and IGF-I measures; fasting glucose, urinary C-peptide, blood pressure and routine chemistry were unchanged [1]. This is another adult exposure study, not proof of improved body composition, long-term safety or a schedule for current compounded products.